Rash caused by lurasidone in old chinese patient with bipolar disorder: case-based review.
Adverse drug reaction
Dose increasing
Lurasidone
Rash
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
08 Jul 2024
08 Jul 2024
Historique:
received:
24
12
2023
accepted:
07
03
2024
medline:
9
7
2024
pubmed:
9
7
2024
entrez:
8
7
2024
Statut:
epublish
Résumé
Rash is one of common adverse drug reaction and which have been reported in typical and atypical antipsychotics. Reports of lurasidone induced skin reactions are sparse. In this study, we report a case of rash caused by lurasidone. A 63-year-old man with bipolar disorder (BD) who is treated by lurasidone. However, the patient presents a rash all over after lurasidone dose increasing from 40 mg/day to 60 mg/day. With the diagnosis of drug induced rash, lurasidone was discontinued, and the rash complete disappears within 2 weeks. In addition, all case reports about antipsychotics associated rash were reviewed by searching English and Chinese database including Pubmed, Embase, Cochrane Library, CNKI and Wanfang database. A total of 139 articles contained 172 patients were included in our study. The literature review and our case suggest that the cutaneous adverse events caused by antipsychotic drugs should not be ignored, particularly for the patient who was first use or at dose increasing of antipsychotic. In conclusion, we report a case of lurasidone related rash and review rash caused by antipsychotics. Psychiatrists should be alert to the possibility of the rash caused by antipsychotics, especially the patient was first use of antipsychotics or the antipsychotic dose was increasing.
Sections du résumé
BACKGROUND
BACKGROUND
Rash is one of common adverse drug reaction and which have been reported in typical and atypical antipsychotics. Reports of lurasidone induced skin reactions are sparse. In this study, we report a case of rash caused by lurasidone.
CASE PRESENTATION
METHODS
A 63-year-old man with bipolar disorder (BD) who is treated by lurasidone. However, the patient presents a rash all over after lurasidone dose increasing from 40 mg/day to 60 mg/day. With the diagnosis of drug induced rash, lurasidone was discontinued, and the rash complete disappears within 2 weeks. In addition, all case reports about antipsychotics associated rash were reviewed by searching English and Chinese database including Pubmed, Embase, Cochrane Library, CNKI and Wanfang database. A total of 139 articles contained 172 patients were included in our study. The literature review and our case suggest that the cutaneous adverse events caused by antipsychotic drugs should not be ignored, particularly for the patient who was first use or at dose increasing of antipsychotic.
CONCLUSIONS
CONCLUSIONS
In conclusion, we report a case of lurasidone related rash and review rash caused by antipsychotics. Psychiatrists should be alert to the possibility of the rash caused by antipsychotics, especially the patient was first use of antipsychotics or the antipsychotic dose was increasing.
Identifiants
pubmed: 38977949
doi: 10.1186/s12888-024-05668-5
pii: 10.1186/s12888-024-05668-5
doi:
Substances chimiques
Lurasidone Hydrochloride
O0P4I5851I
Antipsychotic Agents
0
Types de publication
Journal Article
Case Reports
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
491Subventions
Organisme : Clinical comprehensive evaluation of drugs special research project of Zhejiang Pharmaceutical Association
ID : 2022ZYYL13
Informations de copyright
© 2024. The Author(s).
Références
Ho AM, Coombes BJ, Nguyen TTL, Liu D, McElroy SL, Singh B, Nassan M, Colby CL, Larrabee BR, Weinshilboum RM, Frye MA, Biernacka JM. Mood-stabilizing antiepileptic treatment response in bipolar disorder: a genome-wide Association study. Clin Pharmacol Ther. 2020;108(6):1233–42. https://doi.org/10.1002/cpt.1982 .
doi: 10.1002/cpt.1982
pubmed: 32627186
pmcid: 7669647
Baena-Oquendo S, Valencia JG, Vargas C, López-Jaramillo C. Neuropsychological aspects of bipolar disorder. Rev Colomb Psiquiatr. 2021. https://doi.org/10.1016/j.rcp.2020.08.003 . S0034-7450(20)30092-5.
doi: 10.1016/j.rcp.2020.08.003
Nikolitch K, Saraf G, Solmi M, Kroenke K, Fiedorowicz JG. Fire and darkness: on the Assessment and Management of Bipolar Disorder. Med Clin North Am. 2023;107(1):31–60. https://doi.org/10.1016/j.mcna.2022.04.002 .
doi: 10.1016/j.mcna.2022.04.002
pubmed: 36402499
GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137–50. https://doi.org/10.1016/S2215-0366(21)00395-3 .
doi: 10.1016/S2215-0366(21)00395-3
pmcid: 8776563
McIntyre RS, Berk M, Brietzke E, Goldstein BI, López-Jaramillo C, Kessing LV, Malhi GS, Nierenberg AA, Rosenblat JD, Majeed A, Vieta E, Vinberg M, Young AH, Mansur RB. Bipolar disorders. Lancet. 2020;396(10265):1841–56. https://doi.org/10.1016/S0140-6736(20)31544-0 .
doi: 10.1016/S0140-6736(20)31544-0
pubmed: 33278937
He H, Hu C, Ren Z, Bai L, Gao F, Lyu J. Trends in the incidence and DALYs of bipolar disorder at global, regional, and national levels: results from the global burden of Disease Study 2017. J Psychiatr Res. 2020;125:96–105. https://doi.org/10.1016/j.jpsychires.2020.03.015 .
doi: 10.1016/j.jpsychires.2020.03.015
pubmed: 32251918
de Filippis R, Menculini G, D’Angelo M, Carbone EA, Tortorella A, De Fazio P, Steardo L Jr. Internalized-stigma and dissociative experiences in bipolar disorder. Front Psychiatry. 2022;13:953621. https://doi.org/10.3389/fpsyt.2022.953621 .
doi: 10.3389/fpsyt.2022.953621
pubmed: 35966460
pmcid: 9372275
Dimick MK, Hird MA, Sultan AA, Mitchell RHB, Sinyor M, MacIntosh BJ, Goldstein BI. Resting-state functional connectivity indicators of risk and resilience for self-harm in adolescent bipolar disorder. Psychol Med. 2023;53(8):3377–86. https://doi.org/10.1017/S0033291721005419 .
doi: 10.1017/S0033291721005419
pubmed: 35256032
Chen CK, Yang SY, Park SC, Jang OJ, Zhu X, Xiang YT, Ouyang WC, Javed A, Khan MNS, Grover S, Avasthi A, Kallivayalil RA, Chee KY, Chemi N, Kato TA, Hayakawa K, Pariwatcharakul P, Maramis M, Seneviratne L, Sim K, Tang WK, Oo T, Sartorius N, Tan CH, Chong MY, Park YC, Shinfuku N, Lin SK. Clinical use of mood stabilizers beyond treatment for bipolar disorder: the REAP-MS study. Asian J Psychiatr. 2023;85:103613. https://doi.org/10.1016/j.ajp.2023.103613 .
doi: 10.1016/j.ajp.2023.103613
pubmed: 37163943
Rybakowski JK. Meaningful aspects of the term ‘mood stabilizer’. Bipolar Disord. 2018;20(4):391–92. https://doi.org/10.1111/bdi.12608 .
doi: 10.1111/bdi.12608
pubmed: 29327794
Suran M. Treating bipolar disorder is notoriously difficult, but Research Underway could lead to New options. JAMA. 2023. https://doi.org/10.1001/jama.2023.10057 .
doi: 10.1001/jama.2023.10057
pubmed: 37917079
Rybakowski JK. Mood stabilizers of First and Second Generation. Brain Sci. 2023;13(5):741. https://doi.org/10.3390/brainsci13050741 .
doi: 10.3390/brainsci13050741
pubmed: 37239213
pmcid: 10216063
Singh B, Yocum AK, Strawbridge R, Burdick KE, Millett CE, Peters AT, Sperry SH, Fico G, Vieta E, Verdolini N, Godin O, Leboyer M, Etain B, Tso IF, Coombes BJ, McInnis MG, Nierenberg AA, Young AH, Ashton MM, Berk M, Williams LJ, Keramatian K, Yatham LN, Overs BJ, Fullerton JM, Roberts G, Mitchell PB, Andreassen OA, Andreazza AC, Zandi PP, Pham D, Biernacka JM, Frye MA. FACE-BD collaborators, The Global Bipolar Cohort Collaborative. Patterns of pharmacotherapy for bipolar disorder: a GBC survey. Bipolar Disord. 2023. https://doi.org/10.1111/bdi.13366 .
doi: 10.1111/bdi.13366
pubmed: 37463846
Tarzian M, Soudan M, Alhajji M, Ndrio M, Fakoya AO. Lurasidone for treating Schizophrenia and Bipolar Depression: a review of its efficacy. Cureus. 2023;15(4):e38071. https://doi.org/10.7759/cureus.38071 .
doi: 10.7759/cureus.38071
pubmed: 37228542
pmcid: 10208134
Belmaker RH. Lurasidone and bipolar disorder. Am J Psychiatry. 2014;171(2):131–33. https://doi.org/10.1176/appi.ajp.2013.13091240 .
doi: 10.1176/appi.ajp.2013.13091240
pubmed: 24170243
Chen J. Yi Ru Fang. A novel atypical antipsychotic: Lurasidone. J Clin Psychol Med. 2022;32(1):81. https://doi.org/10.3969/j.issn.1005-3220.2022.01.024
doi: 10.3969/j.issn.1005-3220.2022.01.024
Azhar Y, Shaban K. Lurasidone. In: StatPearls. 2023. PMID: 31082101.
Fiorillo A, Cuomo A, Sampogna G, Albert U, Calò P, Cerveri G, De Filippis S, Masi G, Pompili M, Serafini G, Vita A, Zuddas A, Fagiolini A. Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice. Expert Opin Pharmacother. 2022;23(16):1801–18. https://doi.org/10.1080/14656566.2022.2141568
doi: 10.1080/14656566.2022.2141568
pubmed: 36398838
Takaesu Y, Takeshima M, Watanabe K. Effectiveness and tolerability of Lurasidone for bipolar types I and II and other specified bipolar depression: a 12-Week observational study. J Clin Psychopharmacol. 2022;42(5):485–88. https://doi.org/10.1097/JCP.0000000000001590
doi: 10.1097/JCP.0000000000001590
pubmed: 35916577
Kato M, Masuda T, Sano F, Kato T. The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: a pooled post-hoc analysis of two randomized, placebo-controlled trials. J Affect Disord. 2023;337:150–58. https://doi.org/10.1016/j.jad.2023.05.065
doi: 10.1016/j.jad.2023.05.065
pubmed: 37245552
Goldberg JF, Siu C, Tocco M, Pikalov A, Loebel A. The effect of Lurasidone on anxiety symptoms in patients with bipolar depression: a Post Hoc Analysis. J Clin Psychiatry. 2023;84(4):22m14732. https://doi.org/10.4088/JCP.22m14732
doi: 10.4088/JCP.22m14732
pubmed: 37339360
Ricci V, Di Salvo G, Maina G. Lurasidone in first-episode psychosis with predominant depressive symptoms: a case report. Int Clin Psychopharmacol. 2023;38(4):275–80. https://doi.org/10.1097/YIC.0000000000000465
doi: 10.1097/YIC.0000000000000465
pubmed: 36853746
Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, Song Y, Liu X, Wang M, Zhang L, Kou C. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry. 2017;17(1):373. https://doi.org/10.1186/s12888-017-1539-0
doi: 10.1186/s12888-017-1539-0
pubmed: 29162032
pmcid: 5698995
Naranjo CA, Shear NH, Lanctôt KL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol. 1992;32(10):897–904. https://doi.org/10.1002/j.1552-4604
doi: 10.1002/j.1552-4604
pubmed: 1447396
Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2014;155:20–27. https://doi.org/10.1016/j.jad.2013.10.040
doi: 10.1016/j.jad.2013.10.040
pubmed: 24246116
Shang X, Guo W, Zhu ZY, Zhou JQ, Liu W, Cao MJ, Yao SY. Data analysis of adverse events signals for lurasidone based on FAERS database. Practical Pharm Clin Remedies. 2023;26(4):311–16. https://doi.org/10.14053/j.cnki.ppcr.202304005 .
Hafeez ZH. Exanthematous Rash with Lurasidone in an Elderly Woman with Schizoaffective Disorder. Prim Care Companion CNS Disord. 2019;21(2):18l02370. https://doi.org/10.4088/PCC.18l02370
doi: 10.4088/PCC.18l02370
pubmed: 30947406
Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol. 2007;572(2–3):160–70. https://doi.org/10.1016/j.ejphar.2007.06.058
doi: 10.1016/j.ejphar.2007.06.058
pubmed: 17662268
Haizhen Zhong. Skin rash caused by piropilone: a case report. J Psychiatry. 2014;27(4):287. https://doi.org/10.3969/j.issn.1009-7201.2014.04.016
doi: 10.3969/j.issn.1009-7201.2014.04.016
Cao Y, Bairam A, Liu MC, Uetrecht J. Potential involvement of sulfotransferase in the mechanism of Lamotrigine-induced skin Rash. Chem Res Toxicol. 2023;36(11):1711–16. https://doi.org/10.1021/acs.chemrestox.3c00187
doi: 10.1021/acs.chemrestox.3c00187
pubmed: 37922508
Agbabiaka TB, Savović J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31(1):21–37. https://doi.org/10.2165/00002018-200831010-00003
doi: 10.2165/00002018-200831010-00003
pubmed: 18095744
Bryant CA, Cinibulk M, Manchee C, Cho SH. Running out of options: a case of DRESS with possible neosensitization to Lurasidone in an acutely Manic, psychotic, and Catatonic Patient. J Acad Consult Liaison Psychiatry. 2022;63:S180–1. https://doi.org/10.1016/j.jaclp.2022.10.140
doi: 10.1016/j.jaclp.2022.10.140
Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–97. https://doi.org/10.1016/j.amjmed.2011.01.017
doi: 10.1016/j.amjmed.2011.01.017
pubmed: 21592453
Swati C, Singh H, Bunty S. Case report of olanzapine induced psoriasis in a young adult male with Acute transient psychotic disorder. Indian J Psychiatry. 2022;64(SUPPL 3):S613–4.